Article Text

Download PDFPDF
Novel treatment (new drug/intervention; established drug/procedure in new situation)
A novel treatment of central serous chorioretinopathy with topical anti-inflammatory therapy
  1. Chee-Foong Chong,
  2. David Yang,
  3. Thuan Q Pham,
  4. Henry Liu
  1. Dubbo Eye Centre, Dubbo, New South Wales, Australia
  1. Correspondence to Dr Chee-Foong Chong, fong_cf{at}yahoo.com

Summary

A 45-year-old Caucasian female with diagnosis of central serous chorioretinopathy (CSCR) did not improve on conventional observational approach. She was not willing to proceed with photocoagulation or photodynamic therapy. An unconventional approach of topical anti-inflammatory (ketorolac, dexamethasone and hydrocortisone) preparation was prescribed. The course of her CSCR responded well on this unconventional treatment, but relapsed on cessation or tapering of treatment. After 18 weeks of treatment with a gradual taper, her condition resolved. The present case highlights an alternative but unconventional treatment of CSCR with prolonged use of anti-inflammatories.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.